Sesame Summit 2026 – application open

Five Lives raises €1.7 million to advance digital therapeutics for cognitive decline

Strategic health investors back digital therapeutics for cognitive decline

Europe’s digital health sector is witnessing a quiet but significant shift in investor appetite, with growing capital flows towards therapeutic applications that address chronic neurological conditions — an area historically underserved by both pharmaceutical innovation and venture funding. As populations across the continent age and healthcare systems strain under the weight of dementia-related costs, digital therapeutics platforms that can deliver clinically validated interventions at scale are attracting attention from a new class of strategic health investors.

Five Lives, the Franco-British healthtech startup developing digital therapies for dementia prevention and cognitive decline, has raised €1.7 million from strategic investors Open CNP (the investment arm of French insurance group CNP Assurances), 50 Partners, and Family Ventures. The company is supplementing the round with a crowdfunding campaign on Sowefund, targeting an additional €300,000 to €500,000. Combined with previous rounds totalling over €3 million from investors including Headline, Speedinvest, and Boost Capital, Five Lives has now secured approximately €5 million in total funding.

From prevention to treatment: a dual-product strategy

Founded in 2019 by CEO Xavier Louis, Five Lives has evolved from a consumer-facing brain health app into a clinically validated digital therapeutics platform operating across two distinct product lines. The original Five Lives Mental Health Prevention app targets at-risk individuals without a clinical diagnosis, offering personalised lifestyle guidance across five evidence-based pillars: physical exercise, cognitive stimulation, nutrition, sleep, and social engagement.

In January 2026, the company launched Five Lives Care, a prescription-grade therapeutic application designed specifically for patients with mild cognitive impairment — the clinical stage that often precedes Alzheimer’s disease. The app includes over 500 adapted exercise videos, memory and attention training games, and AI-powered personalised treatment sessions. Within its first two months, Five Lives Care has enrolled 5,000 patients, demonstrating strong early adoption in a market where treatment options for early-stage cognitive decline remain severely limited.

“When diagnosed with Alzheimer today, patients go home with no meaningful medical perspective,” Xavier Louis has noted, highlighting the therapeutic gap that Five Lives aims to address. The company’s approach draws on accumulating clinical evidence that lifestyle interventions can meaningfully slow cognitive decline when delivered early and consistently.

Clinical validation underpins reimbursement strategy

The strength of Five Lives’ positioning lies in its clinical evidence base. A randomised controlled trial conducted across seven hospitals — five in the United Kingdom and two in France (Broca Hospital in Paris and La Timone in Marseille) — involving 180 patients demonstrated significant improvements in executive function and quality of life within three months of using the platform. The new funding will partially finance a second clinical trial, designed to strengthen the company’s case for healthcare reimbursement — a critical milestone that would unlock substantially larger market access.

The reimbursement pathway is central to Five Lives’ revenue model. While the consumer app operates on a subscription basis at approximately €30 per month, the clinical product commands a reimbursement rate of €135 per month. Securing formal reimbursement approval, which the company is targeting for 2027, would transform its unit economics and addressable market. Five Lives projects revenues of €1 million in 2026, rising to €5 to €10 million in 2027 if reimbursement is achieved, with a longer-term ambition of reaching €100 million in annual revenue and 500,000 patients by 2030.

A growing European digital therapeutics market

The investment by Open CNP is strategically significant. As the investment vehicle of CNP Assurances, one of France’s largest insurance groups, its participation signals that major health insurers are beginning to view digital therapeutics as a viable complement to traditional care pathways — and a potential tool for reducing the long-term costs associated with dementia, which currently represent one of the largest financial burdens on European healthcare systems.

Five Lives’ commercial expansion is focused on three markets: France, the United Kingdom, and the United States, with the new capital supporting customer acquisition and AI integration to further personalise treatment protocols. With over 200,000 cumulative app downloads and a growing clinical evidence base, the company is building the foundation for a platform that could scale across Europe’s fragmented but increasingly receptive digital health landscape.


Summary

Company: Five Lives
HQ: France / United Kingdom
Founded: 2019
Round: Funding round
Amount: €1.7 million (+ up to €500k crowdfunding)
Investors: Open CNP (CNP Assurances), 50 Partners, Family Ventures
Use of Funds: Commercial expansion (France, UK, US), second clinical trial, AI integration for personalised treatment

you might also like

Fundraising 2 hours ago

London-based AI laboratory Ineffable Intelligence has emerged from stealth with a $1.1 billion seed round at a $5.1 billion post-money valuation, the company confirmed on 27 April 2026. The financing is the largest seed round ever raised by a European company and one of the largest first-money-in rounds in the global history of artificial intelligence. The round was co-led by Sequoia Capital and Lightspeed Venture Partners. Participating investors included Nvidia, DST Global, Index Ventures, Google, and the UK Sovereign AI Fund, the British government’s recently established vehicle for backing strategic AI capacity on home soil. A bet on a different path to general intelligence Ineffable Intelligence was founded in 2025 by David Silver, the former Vice President of Reinforcement Learning at Google DeepMind and the principal architect of AlphaGo, AlphaZero and AlphaStar. He is joined by three further DeepMind alumni: Wojciech Czarnecki, Lasse Espeholt and Junhyuk Oh. All four have spent the past decade at the frontier of reinforcement learning research, the discipline behind some of the most consequential demonstrations of machine learning over the past ten years. The company describes its objective as building a “superlearner” — an AI system capable of acquiring knowledge directly from its own experience rather than from human-generated text or imagery. “Our mission is to make first contact with superintelligence,” Silver said in a statement accompanying the launch. “We are creating a superlearner that discovers all knowledge from its own experience, from elementary motor skills through to profound intellectual breakthroughs.” The framing is a deliberate departure from the dominant industry trajectory. Most leading AI laboratories, including OpenAI, Anthropic and Google DeepMind itself, have built large language models trained primarily on the corpus of the internet, then refined that training with human feedback. Ineffable’s wager is that the marginal returns on scaling text-based pretraining are diminishing and that the next leap in capability will come from agents that learn endlessly from the consequences of their own actions, in much the same way AlphaZero learnt the game of Go without studying any human matches. Why $1.1 billion at seed The size of the round is unusual even by the inflated standards of the 2026 AI capital cycle. Two factors appear to explain it. First, frontier reinforcement learning at the scale Ineffable describes is computationally extraordinarily expensive: the company will need to operate vast simulation environments and train very large models against them, an undertaking that consumes capital at a rate closer to physical R&D than to traditional software. Second, the round signals a strategic move by Europe’s investor and policy ecosystems to retain the most ambitious AI researchers on the continent. The presence of the UK Sovereign AI Fund alongside Sequoia, Lightspeed and Nvidia is the clearest expression of that intent. The British government has publicly framed the investment as a bet on breakthrough AI that “can discover new knowledge”, positioning the country as a willing co-investor in domestic frontier laboratories. For Ineffable, the implication is access not only to capital but to compute, regulatory engagement and the still-resilient academic talent base around UCL, Oxford, Cambridge and Imperial. Founder pledge of historic scale Alongside the funding announcement, Silver disclosed that he is committing 100 per cent of any personal proceeds from his Ineffable equity to charity via the Founders Pledge network — described by the organisation as the largest pledge in its history. At the round’s $5.1 billion valuation, that commitment could ultimately exceed several billion dollars if the company succeeds. It is a meaningful gesture in a sector where the reputational stakes around concentrated AI wealth are escalating, and one likely to be referenced in subsequent founder-led commitments. Implications for the European AI landscape Ineffable’s emergence reshapes the European AI map in three concrete ways. It establishes London as the home of the continent’s largest-ever seed-stage company, complicating Paris’s recent narrative of frontier-AI primacy after Mistral’s earlier rounds. It validates a thesis — that reinforcement learning, not transformer scaling, is the next frontier — that has lately been losing capital share to language-model incumbents. And it confirms that the UK government is now willing to act as a balance-sheet co-investor in domestic AI laboratories, a posture much closer to the French model than to the predominantly grant-based regimes elsewhere in Europe. The execution risk is non-trivial. Reinforcement learning at frontier scale has historically required years of careful environment design before producing competitive systems, and Ineffable’s “first contact” framing sets a high bar against which it will be judged. But for now, with a billion dollars on the balance sheet, four of the discipline’s most accomplished researchers in the founding team and a sovereign co-investor at its back, Ineffable Intelligence is the most heavily resourced new entrant in the European AI cycle. Sesamers covers European fundraising rounds across deeptech, fintech and AI. Source: tech.eu.

Fundraising 5 days ago

Belfast's Cloudsmith has raised $72M Series C led by TCV, with Insight Partners participating, to expand its artifact management platform and secure the AI-era software supply chain.

Fundraising 5 days ago

Berlin’s VREY has raised €3.3M seed led by Rubio Impact Ventures to roll out rooftop solar software for Germany’s multi-family buildings.

Subscribe to
our Newsletter!

Stay at the forefront with our curated guide to the best upcoming Tech events.